MapLight Therapeutics, Inc.
MPLT Nasdaq Pharmaceutical Preparations Financials FY2024–FY2025
Last close · Oct 23, 2026
$7.97
3.4%What MapLight Therapeutics, Inc. does
No business description yet.
- Legal name
- MapLight Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Accession · CIK
- 0001193125-26-125072
0001770069
Revenue and margins
MapLight Therapeutics, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$139M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
MapLight Therapeutics, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 1,079.1%.
Balance sheet
Cash, debt and the ratios that show how comfortably MapLight Therapeutics, Inc. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $109M | $305M |
| Current ratio | 7.2x | 20.0x |
| Quick ratio | 7.2x | 20.0x |
| Total assets | $137M | $480M |
| Total liabilities | $21.7M | $21.1M |
| Shareholders' equity | −$194M | $458M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✓ |
| Cash from operations exceeds net income | ✕ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✓ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | — |
| F-score | — / 3 | — / 6 |
| Accruals ratio | 0.9% | −7.5% |
| Altman Z'' | −13.45 | 22.17 |
2 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Research and development | $68.5M | $138M |
| Operating income | −$82.9M | −$169M |
| Net income | −$77.6M | −$161M |
| Diluted EPS | −$105.38 | −$18.56 |
| Diluted shares | 0.00B | 0.01B |
| Cash flow | ||
| Cash from operations | −$78.8M | −$138M |
| Capital expenditure | $0.8M | $0.5M |
| Free cash flow | −$79.6M | −$139M |
| Depreciation and amortization | $0.7M | $0.6M |
| Stock-based compensation | $1.1M | $36.0M |
| Balance sheet | ||
| Cash and short-term investments | $109M | $305M |
| Current assets | $115M | $325M |
| Current liabilities | $15.9M | $16.2M |
| Property and equipment, net | $1.2M | $1.1M |
| Total assets | $137M | $480M |
| Total liabilities | $21.7M | $21.1M |
| Shareholders' equity | −$194M | $458M |
| Returns | ||
| Return on capital employed | −68.6% | −36.5% |
| Return on equity | — | −121.7% |
| Return on assets | −56.7% | −52.3% |
| Return on tangible equity | — | −35.2% |
| Growth | ||
| Share count change | — | 1,079.1% |
| Financial health | ||
| Current ratio | 7.2x | 20.0x |
| Quick ratio | 7.2x | 20.0x |
| Quality scores | ||
| Altman Z'' | −13.5 | 22.2 |
| Accruals ratio | 0.9% | −7.5% |
Source: SEC EDGAR XBRL filings (CIK 0001770069). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.